MedTrace Logo

Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC

NCT05066412 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-02-13

No results posted yet for this study

Summary

To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.

Conditions

  • Hematologic Malignancy
  • Haplo-identical Stem Cell Transplantation

Interventions

OTHER

CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology

CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2026-06-02
Completion
2026-12-02

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066412 on ClinicalTrials.gov